Communiqués Cyxone AB

Actions

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 04/07/2024			Varia. 5j.	Varia. 1 janv.
0,101 ^SEK	+1,00%		-8,18%	+0,60%

14/05	Cyxone AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
22/04	Cyxone AB (publ) annonce des changements au niveau du directeur général	CI

Kjell Stenberg new CEO in Cyxone AB	22/04	AQ
BioStock: Cyxone comments on the clinical collaboration in the UK	28/03	AQ
Cyxone enters important research collaboration	25/03	AQ
BioStock: Cyxone's CEO gives a status update	05/03	AQ
BioStock: Cyxone identifies target protein for rabeximod	17/01	AQ
Cyxone reaches important milestone regarding mechanism of action	15/01	AQ
Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor	20/11	AQ
Interim Report 1 January to 30 September 2023	27/10/23	AQ
Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K	09/10/23	AQ
BioStock Investor Meeting: Cyxone	27/09/23	AQ
Interim Report 1 January to 30 June 2023	30/08/23	AQ
Cyxone revises strategy for commercial alignment targeting valuable market opportunities	29/08/23	AQ
Cyxone appoints Urban Ottosson as new CFO	15/06/23	AQ
Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K	31/05/23	AQ
Cyxone : Bulletin of the Annual General Meeting	30/05/23	PU
Bulletin from the annual general meeting in Cyxone AB on 30 May 2023	30/05/23	AQ
Interim Report 1 January to 31 March 2023	12/05/23	AQ
Cyxone receives patent approval from the US for the salt forms of the compound rabeximod	09/05/23	AQ
Cyxone : Annual Report from Cyxone AB for the period 1 January 2022 to 31 December 2022	27/04/23	PU
Cyxone : Nomination Committee proposals and reasoned statement	26/04/23	PU

Aucun résultat pour cette recherche